Form 4 Filing for AC Immune SA - Officer and Director Transactions

This filing details transactions by Martin Zuegel, Interim CEO and Director of AC Immune SA. On June 11, 2026, Zuegel received a grant of 33,136 restricted share units under the company's 2016 Stock Option and Incentive Plan (SOIP). The filing also reports the receipt of share options for 77,778 shares under the same plan, with these options vesting on June 10, 2027. Zuegel holds these securities directly. Following these transactions, his reported holdings include 71,408 common shares underlying restricted units and 77,778 share options. The transactions were reported on Form 4, with the signature date of June 15, 2026.